Literature DB >> 18791708

Disruption of the blood-brain barrier by intra-arterial administration of papaverine: a technical note.

Johannes Platz1, Krisztina Baráth, Emanuela Keller, Anton Valavanis.   

Abstract

INTRODUCTION: Various endovascular techniques can be used to treat cerebral vasospasm after aneurysmal subarachnoid haemorrhage (SAH) including intra-arterial administration of vasodilator drugs such as papaverine or nicardipine and balloon dilatation of the affected vessel segment. Papaverine is known to have side effects, and we report a possible new one.
MATERIALS AND METHODS: After the treatment of cerebral vasospasm in a SAH patient by intra-arterial administration of papaverine into the left posterior cerebral artery, severe mesencephalic extravasation of blood and contrast media was detected.
RESULTS: After reviewing the literature, the authors conclude that interruption of the blood-brain barrier by papaverine most likely combined with a secondary hyperperfusion phenomena, and perhaps a direct toxic effect on brain tissue was the mechanism of this major complication.
CONCLUSION: In treating vasospasm in areas with a high density of perforating arteries, especially in the posterior circulation, papaverine should be used cautiously because a safe regimen has yet to be established. In this situation, alternative agents such as calcium channel blockers could be considered, but evidence-based data are still missing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18791708     DOI: 10.1007/s00234-008-0455-x

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  37 in total

Review 1.  Endovascular treatment of cerebral vasospasm.

Authors:  T P Smith; D S Enterline
Journal:  J Vasc Interv Radiol       Date:  2000-05       Impact factor: 3.464

2.  Intraarterial infusion of high-concentration papaverine damages cerebral arteries in rats.

Authors:  S Yoshimura; N Hashimoto; Y Goto; K Sampei; T Tsukahara; K Iihara
Journal:  AJNR Am J Neuroradiol       Date:  1996 Nov-Dec       Impact factor: 3.825

3.  MMP-9 and EBA immunoreactivity after papaverine mediated opening of the blood-brain barrier.

Authors:  Abesh Kumar Bhattacharjee; Takeshi Kondoh; Mitsuru Ikeda; Eiji Kohmura
Journal:  Neuroreport       Date:  2002-12-03       Impact factor: 1.837

4.  Effect of intra-arterial papaverine on regional cerebral blood flow in hemodynamically relevant cerebral vasospasm.

Authors:  P Vajkoczy; P Horn; C Bauhuf; E Munch; U Hubner; D Ing; C Thome; C Poeckler-Schoeninger; H Roth; P Schmiedek
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

5.  Indications for endovascular therapy for refractory vasospasm after aneurysmal subarachnoid hemorrhage: experience at the University of Cincinnati.

Authors:  Norberto Andaluz; Thomas A Tomsick; John M Tew; Harry R van Loveren; Hwa-Shain Yeh; Mario Zuccarello
Journal:  Surg Neurol       Date:  2002-08

6.  Combined endovascular treatment for both intracranial aneurysm and symptomatic vasospasm.

Authors:  Yuichi Murayama; Joon K Song; Ken Uda; Y Pierre Gobin; Gary R Duckwiler; Satoshi Tateshima; Aman B Patel; Neil A Martin; Fernando Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

7.  Safety and feasibility of intra-arterial nicardipine for the treatment of subarachnoid hemorrhage-associated vasospasm: initial clinical experience with high-dose infusions.

Authors:  J G Tejada; R A Taylor; M S Ugurel; M Hayakawa; S K Lee; J C Chaloupka
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

8.  Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm.

Authors:  W McAuliffe; M Townsend; J M Eskridge; D W Newell; M S Grady; H R Winn
Journal:  J Neurosurg       Date:  1995-09       Impact factor: 5.115

9.  Multimodal quantitation of the effects of endovascular therapy for vasospasm on cerebral blood flow, transcranial doppler ultrasonographic velocities, and cerebral artery diameters.

Authors:  Rod J Oskouian; Neil A Martin; Jae Hong Lee; Thomas C Glenn; Donald Guthrie; Nestor R Gonzalez; Arash Afari; Fernando Viñuela
Journal:  Neurosurgery       Date:  2002-07       Impact factor: 4.654

10.  Intra-arterially administered papaverine for the treatment of symptomatic cerebral vasospasm.

Authors:  R S Polin; C A Hansen; P German; J B Chadduck; N F Kassell
Journal:  Neurosurgery       Date:  1998-06       Impact factor: 4.654

View more
  7 in total

1.  Vasogenic edema of the Basal Ganglia after intra-arterial administration of nimodipine for treatment of vasospasm.

Authors:  Chang-Woo Ryu; Jun-Seok Koh; Seung-Young Yu; Eui-Jong Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-02-28

2.  Verapamil-induced breakdown of the blood-brain barrier presenting as a transient right middle cerebral artery syndrome.

Authors:  Jonathan Pace; Jeffrey Nelson; Abhishek Ray; Yin Hu
Journal:  Interv Neuroradiol       Date:  2017-09-28       Impact factor: 1.610

3.  Manipulation of olfactory tight junctions using papaverine to enhance intranasal delivery of gemcitabine to the brain.

Authors:  Mansi Krishan; Gary A Gudelsky; Pankaj B Desai; Mary Beth Genter
Journal:  Drug Deliv       Date:  2013-10-14       Impact factor: 6.419

Review 4.  Current options for the management of aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm: a comprehensive review of the literature.

Authors:  Guilherme Dabus; Raul G Nogueira
Journal:  Interv Neurol       Date:  2013-10

5.  Effectiveness of papaverine cisternal irrigation for cerebral vasospasm after aneurysmal subarachnoid hemorrhage and measurement of biomarkers.

Authors:  Jae Hoon Kim; Hyeong-Joong Yi; Yong Ko; Young-Soo Kim; Dong-Won Kim; Jae-Min Kim
Journal:  Neurol Sci       Date:  2013-12-03       Impact factor: 3.307

Review 6.  Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury.

Authors:  Fatima A Sehba; Ryszard M Pluta; John H Zhang
Journal:  Mol Neurobiol       Date:  2010-12-15       Impact factor: 5.590

Review 7.  Blood-Brain Barrier Modulation to Improve Glioma Drug Delivery.

Authors:  Huilong Luo; Eric V Shusta
Journal:  Pharmaceutics       Date:  2020-11-12       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.